Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study

Fig. 2

Clinical outcomes associated with second-line sintilimab plus docetaxel therapy. Waterfall plot (A) and swimmers plot (B) illustrating the best change in tumor size and duration of response of each of the 30 patients who received sintilimab plus docetaxel as second-line therapy. Clinical details and the PD-L1 tumor proportion score (TPS) subgroup of each patient were indicated by different colors

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us